Overview

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

Status:
Not yet recruiting

Trial end date:
2028-07-05

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.

Phase:

Phase 3

Details

Lead Sponsor:

Alexion Pharmaceuticals

Treatments:

Ravulizumab